Technical Analysis for SYBX - Synlogic, Inc.

Grade Last Price % Change Price Change
D 1.90 -0.52% -0.01
SYBX closed up 3.8 percent on Tuesday, April 23, 2024, on approximately normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: May 9
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
200 DMA Resistance Bearish -0.52%
Pocket Pivot Bullish Swing Setup -0.52%
Bollinger Band Squeeze Range Contraction -0.52%
Upper Bollinger Band Walk Strength -0.52%
BB Squeeze + Upper Band Touch Range Contraction -0.52%
Above Upper BB Strength -0.52%
Upper Bollinger Band Touch Strength -0.52%
200 DMA Resistance Bearish 3.26%
20 DMA Support Bullish 3.26%
50 DMA Support Bullish 3.26%

   Recent Intraday Alerts

Alert Time
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
Fell Below Upper Bollinger Band about 2 hours ago
Rose Above Previous Day's High about 23 hours ago
Up 5% about 23 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synlogic, Inc. Description

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Genetic Diseases Metabolism Synthetic Biology Inborn Errors Of Metabolism Rare Genetic Disease Rare Genetic Diseases Newborn Screening Intellectual Disability Phenylketonuria Pku Urea Cycle

Is SYBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.708
52 Week Low 0.234
Average Volume 60,856
200-Day Moving Average 1.91
50-Day Moving Average 1.82
20-Day Moving Average 1.80
10-Day Moving Average 1.82
Average True Range 0.12
RSI (14) 55.75
ADX 19.85
+DI 19.93
-DI 9.09
Chandelier Exit (Long, 3 ATRs) 1.59
Chandelier Exit (Short, 3 ATRs) 2.07
Upper Bollinger Bands 1.88
Lower Bollinger Band 1.72
Percent B (%b) 1.19
BandWidth 9.08
MACD Line -0.02
MACD Signal Line -0.05
MACD Histogram 0.0281
Fundamentals Value
Market Cap 17.55 Million
Num Shares 9.19 Million
EPS -12.68
Price-to-Earnings (P/E) Ratio -0.15
Price-to-Sales 43.51
Price-to-Book 0.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.08
Resistance 3 (R3) 2.07 2.02 2.05
Resistance 2 (R2) 2.02 1.97 2.02 2.04
Resistance 1 (R1) 1.96 1.95 1.99 1.97 2.03
Pivot Point 1.91 1.91 1.92 1.91 1.91
Support 1 (S1) 1.85 1.86 1.88 1.86 1.79
Support 2 (S2) 1.80 1.84 1.80 1.78
Support 3 (S3) 1.74 1.80 1.77
Support 4 (S4) 1.75